Theolytics is developing category changing oncolytic virus cancer therapies. The company is pioneering a phenotypic screening approach to the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. Theolytics, which was founded in 2017 and is headquartered in Oxford, UK, is backed by international life sciences investors Taiho Ventures, Epidarex Capital, and M Ventures, as well as Oxford Science Innovation (OSI).

Team Member
more about
Therese Liechtenstein
Investment Director
Latest News Entry
Theolytics presents CAF-targeting therapy for stromal rich tumours, and strengthens leadership team

Theolytics, a biotechnology company harnessing viruses to combat disease, will release data on their proprietary systemic therapy for stromal-rich tumours at the 2022 International Oncolytic Virus Conference, and announce executive appointments.

Theolytics' £1M project with InnovateUK to develop a novel therapy for multiple myeloma patients

Theolytics kick-starts a £1M project in collaboration with The University of Sheffield, supported by Innovate UK, to develop a novel therapy for multiple myeloma patients in need

Theolytics expands Series A financing and welcomes M Ventures as a new investor

Theolytics is harnessing viruses to combat cancer: transforming patients’ lives; through world leading science; with a great team.

all portfolio news